CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $4.58M, lower than 95% of all stocks globally
- PositionCurrent ratio is 0.8×, lower than 95% of its Biotechnology peers (median 5.71×)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
345.89MUSDvs all stocks (USD)
Revenue (TTM)
4.58MUSDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
2.21xvs all stocks
52-Week Change
-29.66%vs all stocks
Market Capitalization
345.89MUSDvs all stocks (USD)
Enterprise Value
333.83MUSDvs all stocks (USD)
Forward P/E
-3.82xvs Biotechnology peers
Price to Sales (TTM)
75.51xvs Biotechnology peers
Enterprise to Revenue
72.87xvs Biotechnology peers
Enterprise to EBITDA
-4.97xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
-1105.11%vs Biotechnology peers
Return on Assets (TTM)
-48.44%vs Biotechnology peers
Revenue (TTM)
4.58MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.0140USDUpdated Sep 28, 2026Quarterly Revenue Growth
8.40%vs Biotechnology peers
Gross Profit (TTM)
-39.18MUSDvs all stocks (USD)
EBITDA (TTM)
-67.17MUSDvs all stocks (USD)
Net Income (TTM)
-81.81MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
8.38%vs Biotechnology peers
Operating Cash Flow (TTM)
-60.87MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-1.97MUSDvs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Revenue
4.41MUSDFY2025 · Dec 31, 2025Operating Income
-62.92MUSDvs all stocks (USD)
Pre-tax Income
-67.85MUSDFY2025 · Dec 31, 2025Net Income
-67.85MUSDFY2025 · Dec 31, 2025EBIT
-62.66MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-60.27MUSDFY2025 · Dec 31, 2025Research & Development
39.75MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
27.58MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
922.00KUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
5.19MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-67.85MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-57.67MUSDFY2025 · Dec 31, 2025Free Cash Flow
-57.85MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
18.89MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-67.85MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
2.39MUSDFY2025 · Dec 31, 2025Stock-based Compensation
7.71MUSDFY2025 · Dec 31, 2025Other Non-cash Items
1.31MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-1.23MUSDFY2025 · Dec 31, 2025Capital Expenditures
-185.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-126.00KUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-311.00KUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Long-term Debt Payments
-1.00MUSDFY2025 · Dec 31, 2025Other Financing Charges
-1.53MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-2.53MUSDFY2025 · Dec 31, 2025Shares Outstanding
339.04MSharesUpdated Sep 28, 2026Float Shares
333.78MSharesUpdated Sep 28, 2026Shares Short
106.06MSharesUpdated Sep 28, 2026Short Ratio
15.79daysvs all stocks
Short % of Shares Outstanding
31.44%vs all stocks
% Held by Insiders
1.54%vs all stocks
% Held by Institutions
43.41%vs all stocks
Total Cash (MRQ)
100.05MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.2950USDUpdated Sep 28, 2026Total Debt (MRQ)
87.99MUSDvs all stocks (USD)
Current Ratio (MRQ)
0.8020xvs Biotechnology peers
Book Value per Share (MRQ)
-0.0490USDUpdated Sep 28, 2026Total Assets
43.52MUSDvs all stocks (USD)
Total Current Assets
24.34MUSDFY2025 · Dec 31, 2025Total Liabilities
55.68MUSDFY2025 · Dec 31, 2025Total Non-current Assets
19.18MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
32.64MUSDFY2025 · Dec 31, 2025Total Current Liabilities
23.04MUSDFY2025 · Dec 31, 2025Cash
18.57MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
18.57MUSDFY2025 · Dec 31, 2025Accounts Payable
6.20MUSDFY2025 · Dec 31, 2025Short-term Debt
2.11MUSDFY2025 · Dec 31, 2025Deferred Revenue
5.91MUSDFY2025 · Dec 31, 2025Other Current Liabilities
3.39MUSDFY2025 · Dec 31, 2025Long-term Debt
31.04MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
1.60MUSDFY2025 · Dec 31, 2025Common Stock (Book)
3.13MUSDFY2025 · Dec 31, 2025Retained Earnings
-408.07MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
-12.17MUSDvs all stocks (USD)
Treasury Stock
48.00KUSDFY2025 · Dec 31, 202552-Week Low
0.9700USDUpdated Sep 28, 202652-Week High
2.73USDUpdated Sep 28, 202652-Week Change
-29.66%vs all stocks
Beta
2.21xvs all stocks
50-Day MA
1.25USDUpdated Sep 28, 2026200-Day MA
1.50USDUpdated Sep 28, 2026Avg 10-Day Volume
8.34MSharesUpdated Sep 28, 2026Avg 30-Day Volume
6.94MSharesUpdated Sep 28, 2026Diluted EPS (TTM)
-0.2600USDUpdated Sep 28, 2026Other Income / Expense
-664.00KUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Decline With Range Expansion And Drawdown
The price is falling, swinging wider than usual, and sits well below its peak.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 0.8×, lower than 95% of its Biotechnology peers (median 5.71×)Significant
Current ratio: 0.80Industry median: 5.71Industry P5: 1.02Peers compared: 260
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.77
High structural barrier to entryNotable
Barrier to Entry: 361.072
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $4.58M, lower than 95% of all stocks globallySignificant
Revenue (USD): 4,581,000Global P5: 33,357,653.812
Companies that share the same coordination system — how they create, deliver, or capture value.
Enanta Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Surrozen, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Zhejiang Zhenyuan Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Hainan Huluwa Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jilin Jian Yisheng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Emergent BioSolutions Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu GDK Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shoulder Innovations, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Cabaletta Bio Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Bionote Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Mingxin New Material Co. Ltd.
1 interpretationDecline With Range Expansion And Drawdown
Changzhou Kaidi Electrical Co., Ltd.
1 interpretationDecline With Range Expansion And Drawdown
Hebei Changshan Biochemical Pharmaceutical Co., Ltd.
1 interpretationDecline With Range Expansion And Drawdown